163,614 Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 163,614 shares of the medical device company's stock, valued at approximately $5,893,000. Raymond James Financial Inc. owned approximately 0.25% of Tandem Diabetes Care at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. AlphaQuest LLC raised its position in Tandem Diabetes Care by 138.7% during the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after acquiring an additional 541 shares during the period. Jones Financial Companies Lllp increased its stake in shares of Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after purchasing an additional 748 shares in the last quarter. Assetmark Inc. raised its position in shares of Tandem Diabetes Care by 77.5% during the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after purchasing an additional 535 shares during the last quarter. McIlrath & Eck LLC purchased a new position in Tandem Diabetes Care in the 3rd quarter valued at about $52,000. Finally, Smartleaf Asset Management LLC boosted its holdings in Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock worth $65,000 after buying an additional 1,101 shares during the last quarter.

Wall Street Analyst Weigh In

TNDM has been the topic of several research reports. Wells Fargo & Company restated an "equal weight" rating and issued a $22.00 target price (down previously from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Robert W. Baird reduced their target price on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a research report on Thursday, February 27th. Royal Bank of Canada decreased their price target on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Mizuho started coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They set a "neutral" rating and a $20.00 price objective for the company. Finally, Citigroup lowered shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $35.00 to $24.00 in a research note on Tuesday, March 4th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has an average rating of "Moderate Buy" and a consensus price target of $43.81.

Tandem Diabetes Care Trading Down 3.3 %

Shares of NASDAQ TNDM traded down $0.59 during mid-day trading on Monday, reaching $17.47. 1,140,892 shares of the company's stock were exchanged, compared to its average volume of 1,503,446. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -9.05 and a beta of 1.52. Tandem Diabetes Care, Inc. has a 52-week low of $15.75 and a 52-week high of $53.69. The company's 50-day moving average is $20.17 and its 200-day moving average is $29.17. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.

Insiders Place Their Bets

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is currently owned by insiders.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.